Recent research on immunotherapy for anti-N-methyl-D-aspartate receptor encephalitis.
10.7499/j.issn.1008-8830.2204021
- Author:
Yu-Hang LI
1
;
Li JIANG
1
Author Information
1. Department of Neurology, Children's Hospital of Chongqing Medical University/National Clinical Research Center for Child Health and Disorders/Ministry of Education Key Laboratory of Child Development and Disorders/Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China.
- Publication Type:Review
- Keywords:
Anti-N-methyl-D-aspartate receptor encephalitis;
Bortezomib;
Child;
Immunotherapy;
Rituximab monoclonal antibody
- MeSH:
Anti-N-Methyl-D-Aspartate Receptor Encephalitis;
Humans;
Immunotherapy;
Receptors, N-Methyl-D-Aspartate;
Retrospective Studies
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(8):948-953
- CountryChina
- Language:English
-
Abstract:
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a central nervous system disease characterized by neurological and psychiatric symptoms. Immunotherapy is the basic treatment for this disease, including first- and second-line therapies for the acute stage and the long-course therapy for the chronic stage. Anti-NMDAR encephalitis often has a good prognosis, but some patients may still have neurological dysfunction due to poor response to current immunotherapy. In addition, the adverse reactions and economic burden of drugs are practical problems in clinical practice. To solve the above problems, continuous improvements have been made in immunotherapy regimens in terms of dose, route of administration, and course of treatment, and some new immunotherapy drugs have emerged. This article reviews the recent research on immunotherapy for anti-NMDAR encephalitis.
